Renal transplantation in patients with end-stage renal disease due to HCV infection

Kidney transplantation for patients with end-stage renal disease and hepatitis C virus infection remains the preferred form of renal replacement therapy when pretransplant evaluation excludes advanced liver injury. Although infection is associated with inferior long-term outcomes among transplant recipients, transplantation provides a substantial survival advantage over remaining on dialysis and therefore turns HCV status from an apparent barrier into a condition requiring structured risk assessment and management.

Clinical Rationale and Survival Advantage

Patients with HCV infection on dialysis carry a high comorbidity burden and may have liver disease, diabetes mellitus, and other complications that affect candidacy. HCV-related liver disease is often clinically silent during long-term dialysis, while fatigue, cognitive impairment, and other symptoms common in non-dialysis HCV populations are difficult to distinguish from the effects of dialysis itself. Even so, HCV infection is associated with impaired outcomes, including reduced mental quality of life and increased mortality in end-stage renal disease.

Comparative studies consistently favor transplantation over continued dialysis for suitable HCV-infected candidates. In one analysis, transplanted anti-HCV-positive patients had lower mortality than those who remained on the waiting list; another reported a relative risk of death of 0.31 during the 7–48 months after transplantation. In a cohort of 175 listed candidates with documented infection, mortality was initially higher during the first six months after transplantation, with a hazard ratio of 2.51, but fell to 0.32 during months 7–84. The early hazard therefore did not erase the later survival benefit. The evidence supports transplantation as the treatment of choice for HCV-infected patients with end-stage renal disease, provided that the liver can tolerate the procedure and subsequent immunosuppression.

Screening and Liver Assessment

The transplant evaluation begins by distinguishing antibody evidence of exposure from active viral infection. Candidates should be screened for anti-HCV antibodies and, where appropriate, active viremia with nucleic acid testing. Studies have found advanced liver injury, including stage 3 or 4 fibrosis and cirrhosis, in approximately 10–25% of candidates undergoing biopsy during pretransplant assessment. Because noninvasive tests have not provided comparable accuracy and reliability, liver biopsy remains the reference method for staging liver disease in patients with active infection.

The central decision is whether the candidate can safely undergo kidney-alone transplantation. Established or decompensated cirrhosis should prompt referral to a liver transplant team for consideration of simultaneous liver–kidney transplantation. Well-compensated cirrhosis requires more discriminating assessment because kidney transplantation alone may still be considered in selected patients, but cirrhosis increases perioperative morbidity and mortality, susceptibility to infectious and metabolic complications, and the risk of inferior long-term survival. A consensus approach has proposed portal-hypertension criteria, including a wedge hepatic vein pressure below 10 mm Hg, to help distinguish candidates for kidney-alone transplantation from those who should be listed for combined transplantation; some programs additionally consider the absence of varices on endoscopy and a platelet count above 120 × 10^3/µl. In a single-center series, ten-year survival after transplantation was only 26% among the few patients with cirrhosis documented before transplantation.

Waiting-List Surveillance and Treatment Timing

Evaluation does not end when a patient is placed on the waiting list. In regions with prolonged waits approaching five to seven years, HCV-infected candidates require a formal surveillance protocol to ensure that progressive liver disease has not changed their eligibility. Candidates never previously tested should undergo antibody screening with nucleic acid confirmation in low-prevalence settings, or direct nucleic acid testing where prevalence is high. A positive nucleic acid result should place the candidate on hold status and trigger hepatology referral for evaluation and possible treatment.

Candidates who achieved a sustained virologic response before listing should undergo nucleic acid testing at least annually to confirm that the response persists. Those who relapse should be placed on hold and referred for consideration of retreatment. Candidates who remain viremic should receive annual assessment of liver disease. Progression while waiting can be substantial: among 13 patients who underwent repeat biopsy during the waiting period, 8, or 62%, showed worsening histology, compared with only 7 of 31, or 23%, whose repeat biopsies were obtained after transplantation. For patients with Metavir stage 1 or 2 fibrosis, repeat biopsy was recommended every five years; stage 3 disease warranted reassessment after three years. Progression to early or established cirrhosis required removal from the kidney waiting list and referral for consideration of simultaneous liver–kidney transplantation.

Antiviral treatment is generally more strategically valuable before transplantation than afterward. The rationale is not only the possibility of achieving sustained virologic response, but also the increased risk of liver disease progression under immunosuppression and the danger that posttransplant interferon will damage the renal allograft. Interferon-based therapy has been associated with acute rejection in 40–100% of treated kidney recipients, plausibly through cytokine and HLA upregulation. KDIGO therefore recommended that patients should not undergo transplantation while receiving interferon and should remain on hold until treatment is completed. The balance is difficult: therapy can be prolonged, expensive, poorly tolerated, and ineffective in some patients, and dose reduction occurs in 35–42%, with discontinuation in about 30%. Flu-like symptoms, anemia, neutropenia, depression, and anxiety can further erode quality of life.

Outcomes and Residual Risks

HCV-positive recipients have generally shown worse long-term survival than HCV-negative recipients, particularly in studies extending beyond ten years after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79, with liver-related death contributing to the excess. These findings must be interpreted cautiously because many studies were retrospective, classified infection by ELISA rather than nucleic acid testing, and lacked pretransplant biopsies capable of separating preexisting liver damage from posttransplant effects.

The kidney allograft can also be affected. In one comparison of 488 anti-HCV-positive recipients with 2,877 seronegative recipients, the adjusted relative risk of graft loss was 1.53. Registry data from Australia and New Zealand found worse five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss was more often attributed to glomerulonephritis, with an adjusted hazard ratio of 2.71, and chronic allograft nephropathy, with an adjusted hazard ratio of 1.87. HCV-positive recipients also face increased infection-related mortality, although the relative effects of individual immunosuppressive drugs require further study.

Despite these hazards, the clinical comparison remains decisive: for an HCV-infected patient without advanced liver injury, the risks of transplantation are outweighed by the poorer prospects of remaining on dialysis. The procedure does not remove the need for virologic monitoring or liver surveillance, but it offers a survival advantage while creating a new set of posttransplant concerns, including recurrent liver injury, infection, graft disease, and the consequences of immunosuppression.

Allocation, Transmission, and Patient Choice

Organ scarcity adds a second layer to the decision. HCV infection is transmissible through transplantation, and many centers have historically rejected kidneys from HCV-positive donors. Yet the shortage of donated organs means that discarding such kidneys can lengthen waiting times and expose HCV-positive candidates to the mortality of prolonged dialysis. For patients who cannot tolerate, decline, fail, or complete antiviral therapy, transplantation with an HCV-positive kidney may offer a more favorable course than continued dialysis and may shorten the wait.

This option requires explicit selection and consent. Evidence from Spanish transplant groups showed that transplanting kidneys from HCV-positive donors into HCV-positive recipients does not completely prevent transmission, so the practice should be restricted to candidates with positive HCV RNA who have consented in advance. The broader policy is therefore not indiscriminate use, but a negotiated exchange between a known infectious risk and the demonstrated survival advantage of receiving a kidney sooner. In this framework, HCV status determines surveillance, treatment timing, donor selection, and consent, but does not by itself justify withholding transplantation.